valuation risk

Analysts warn investors to sell Micron and Intel, citing temporary supply tailwinds for Micron and persistent challenges at Intel threatening valuations.

Astera Labs experiencing rapid AI-driven growth but faces margin pressures and Amazon concentration risks. Stock's trajectory hinges on operational execution amid premium valuation.

Micron posts 196% revenue growth to $23.86B on AI demand, but stock retreats over $25B capex plans amid cyclical market concerns.

Keysight surges 80% in 52 weeks on AI and defense demand, reports 23% revenue growth to $1.6B, raises guidance to 20% growth. Valuation leaves limited upside.

Tesla's $44B balance sheet and vertical integration offer recession protection, but its 475 P/E ratio risks sharp stock declines despite operational resilience.

Oklo stock surged 160% but fell 65% from peaks, despite zero revenue and $9.7B valuation. Meta deal looks promising, but regulatory delays and execution risks make it a risky bet.

Micron doubles revenue and expands margins to 66% on AI demand, betting $200B to expand memory capacity by 2027. Current 11.5x P/E valuation looks attractive, but execution risks loom.

Intuitive Surgical posted strong Q4 results with 19% revenue growth, but 2026 guidance signals meaningful deceleration. At 63x earnings, stock appears fairly valued for current shareholders but overvalued for new investors.

$UBER fell 12% in three months despite 22% growth and surging free cash flow, as autonomous vehicle competition from Waymo, Tesla, and Amazon's Zoox weighs on investors' long-term outlook.

AST SpaceMobile trades at 382x sales with major carrier partnerships. Massive upside potential offset by execution risk and minimal current operations.

Bloom Energy stock surges 602% on AI data center demand, backed by $20B backlog and $5B Brookfield deal, but 63x 2027 P/E valuation warrants profit-taking despite strong long-term prospects.

Rocket Lab's OSI acquisition accelerates Neutron development and expands defense exposure, positioning for 2027 growth. Yet elevated valuation leaves minimal room for execution errors.

Eli Lilly's GLP-1 success masks valuation risks; P/E of 44 leaves little room for competitive pressure and patent cliff execution.

Tesla shifts focus to robotaxis and humanoid robots amid declining vehicle sales and earnings. Massive upside potential offset by execution risks and stretched valuation.

CoreWeave stock plunged 25% despite 110% revenue growth, as operating losses accelerate and the company plans massive $30-35B capex in 2026 amid heavy debt.

Analysis flags Rivian, Snowflake, Lucid, Palantir, DoorDash, Upstart, and Carvana as overvalued despite weak free cash flow generation, signaling potential volatility ahead.

Palantir surged 11% on strong earnings showing 70% revenue growth, but 80x sales valuation leaves little room for error. Analysts recommend waiting for better entry points.

Nu Holdings' 31x P/E valuation faces pressure as investors gauge credit discipline and asset quality resilience during potential economic stress.

Nvidia shows strong 62% revenue growth and robust AI demand, but its 48x forward earnings valuation raises concerns about downside risks versus potential returns.

Blue Owl's attractive 8.7-9% dividend yield masks risks from concentrated private credit exposure, redemption pressures, and potential reliance on share dilution to sustain payouts.